{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:00:19Z","timestamp":1776722419239,"version":"3.51.2"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Dalpiciclib is a cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor that plays a key role in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER-2)-negative breast cancer. However, there have been no reports of acute liver failure in Hepatitis B virus (HBV) carriers caused by HBV reactivation induced by dalpiciclib. We present a 50-year-old female with recurrent breast cancer and a history of asymptomatic HBV carriage. After dalpiciclib initiation, she developed progressive liver impairment, with hepatitis B virus DNA (HBV DNA) escalating from 1.02 \u00d7 103 to 2.13 \u00d7 10\n                    <jats:sup>6<\/jats:sup>\n                    IU\/ml and HBeAg seroconversion from negative to positive, confirming HBV reactivation. Notably, the patient received initial dalpiciclib-based therapy at an external hospital, where antiviral prophylaxis was not initiated despite the availability of baseline HBV serological and viral load data, due to the failure to conduct clinical risk stratification for HBV reactivation based on these results\u2014a critical gap in pre-therapy assessment for HBV-related risk stratification. Entecavir antiviral therapy led to suppressed viral replication and improved liver function during follow-up. This case emphasizes the need for HBV screening and close monitoring of viral markers\/liver function in asymptomatic HBV carriers receiving dalpiciclib, as early antiviral intervention prevents severe liver complications. It also highlights the importance of clinical pharmacist-led medication follow-up management for outpatients receiving targeted anticancer therapy to avoid oversight of comorbidities and associated prophylactic treatment.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1769544","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:58:26Z","timestamp":1773817106000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Dalpiciclib induced hepatitis B virus reactivation leading to liver failure: a rare case report and review of the literature"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuchen","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Central Hospital of Dalian University of Technology","place":["Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalin","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Central Hospital of Dalian University of Technology","place":["Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aili","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Central Hospital of Dalian University of Technology","place":["Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanli","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Central Hospital of Dalian University of Technology","place":["Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229in","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst."},{"key":"B3","doi-asserted-by":"publisher","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1158\/1078-0432.CCR-23-2975","article-title":"Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor-positive breast cancer","volume":"30","author":"Guarducci","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","article-title":"Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1116073","DOI":"10.3389\/fphar.2023.1116073","article-title":"A mass balance study of [(14)C] SHR6390 (dalpiciclib), a selective and potent CDK4\/6 inhibitor in humans","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/cas.13957","article-title":"Preclinical characterization of SHR6390, a novel CDK 4\/6 inhibitor, in vitro and in human tumor xenograft models","volume":"110","author":"Long","year":"2019","journal-title":"Cancer Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-021-00271-2","article-title":"A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor in Chinese patients with advanced breast cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomark Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nat Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"19ol","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat Rev Immunol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/1874357901812010026","article-title":"Epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma","author":"Petruzziello","year":"2018","journal-title":"Open Virol J."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.015","article-title":"The global burden of liver disease","author":"Younossi","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1184952","DOI":"10.3389\/fonc.2023.1184952","article-title":"Ribociclib in newly diagnosed hepatitis B infection: a case report","volume":"13","author":"Di Costanzo","year":"2023","journal-title":"Front Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2169\/internalmedicine.5678-20","article-title":"Hepatitis B virus reactivation 55 months following chemotherapy including rituximab and autologous peripheral blood stem cell transplantation for malignant lymphoma","volume":"60","author":"Hara","year":"2021","journal-title":"Intern Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.55563\/clinexprheumatol\/qh1gj3","article-title":"Risk of rituximab-induced hepatitis B flare after antiviral discontinuation in rheumatic patients with chronic hepatitis B virus","volume":"42","author":"Lan","year":"2024","journal-title":"Clin Exp Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion","author":"Papatheodoridis","year":"2022","journal-title":"J Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cld.2020.01.010","article-title":"Clinical manifestations of hepatic encephalopathy","volume":"24","author":"Dellatore","year":"2020","journal-title":"Clin Liver Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"267y","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.06.019","article-title":"Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment","author":"Yoo","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1832731","article-title":"Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center","author":"Ito","year":"2021","journal-title":"Mod Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.14238","article-title":"Fatal acute hepatic failure secondary to thrombotic portal venopathy after commencing abemaciclib and fulvestrant treatment for advanced breast carcinoma: a unique autopsy finding","author":"Haynes","year":"2021","journal-title":"Breast J."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj-2021-0015","article-title":"Palbociclib-induced severe hepatitis: a case study and literature review","author":"Hyppolite","year":"2021","journal-title":"Can Liver J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"101098","DOI":"10.1016\/j.jhepr.2024.101098","article-title":"CDK4\/6 inhibitor-induced liver injury: clinical phenotypes and role of corticosteroid treatment","volume":"6","author":"Meunier","year":"2024","journal-title":"JHEP Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s00432-025-06336-1","article-title":"Management of hepatotoxicity associated with CDK4\/6 inhibitors and rechallenge strategies in metastatic hormone-positive, HER2-NEGATIVE BREAST CANCER","volume":"151","author":"Ilhan","year":"2025","journal-title":"J Cancer Res Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3760\/cma.j.cn501113-20221204-00607","volume":"30","year":"2022","journal-title":"Chin J Hepatol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","author":"Kusumoto","year":"2019","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1174ct","DOI":"10.1177\/10781552251340613","article-title":"Rechallenge of an alternative CDK 4\/6 inhibitor after hepatotoxicity in the treatment of hormone-positive metastatic breast cancer","volume":"31","author":"Jackson","year":"2025","journal-title":"J Oncol Pharm Pract."},{"key":"B31","doi-asserted-by":"publisher","first-page":"89ugs","DOI":"10.1097\/CAD.0000000000001529","article-title":"Successful continuance of CDK4\/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report","volume":"35","author":"Ozawa","year":"2024","journal-title":"Anticancer Drugs."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1159\/000549179","article-title":"Ribociclib-induced hepatitis: a case report of possible autoimmune hepatotoxicity","volume":"18","author":"Leigh","year":"2025","journal-title":"Case Rep Oncol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.10.007","article-title":"Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia","author":"Fuentes-Antr\u00e1ntrtes-Antr0549179pez de Se SAnOca\u00f1a","year":"2020","journal-title":"Breast"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1769544\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:58:29Z","timestamp":1773817109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1769544\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":33,"alternative-id":["10.3389\/fmed.2026.1769544"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1769544","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1769544"}}